An integrative 'Omics' solution to the detection of recombinant human erythropoietin and blood doping

British Journal of Sports Medicine

Volumn 48, Issue 10, 2014, Pages 856-861

  Pitsiladis, Yannis P ^a   Durussel, Jérôme ^b   Rabin, Olivier ^c  

^a UNIVERSITY OF BRIGHTON   (United Kingdom)

^b Institute of Health and Wellbeing College of Medical Veterinary and Life Sciences   (United Kingdom)

^c World Anti Doping Agency (WADA)   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; PERFORMANCE ENHANCING SUBSTANCE; RECOMBINANT PROTEIN;

DOPING; GENE EXPRESSION PROFILING; HUMAN; PREVENTION AND CONTROL; PROCEDURES; SUBSTANCE ABUSE;

DOPING IN SPORTS; ERYTHROPOIETIN; GENE EXPRESSION PROFILING; HUMANS; PERFORMANCE-ENHANCING SUBSTANCES; RECOMBINANT PROTEINS; SUBSTANCE ABUSE DETECTION;

EID: 84899904232     PISSN: 03063674     EISSN: 14730480     Source Type: Journal    
DOI: 10.1136/bjsports-2014-093529     Document Type: Review

References (57)

1. Jelkmann W. Regulation of erythropoietin production. J Physiol 2011;589:1251-8.
2. Eschbach JW, Varma A, Stivelman JC. Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia? Nephrol Dial Transplant 2002;17(Suppl 5):2-7.
3. Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985;313:806-10.
4. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985;82:7580-4.
5. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989;35:134-48.
6. Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: A study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102:301-15.
7. Ekblom B, Goldbarg AN, Gullbring B. Response to exercise after blood loss and reinfusion. J Appl Physiol 1972;33:175-80.
8. Cazzola M. A global strategy for prevention and detection of blood doping with erythropoietin and related drugs. Haematologica 2000;85:561-3.
9. Eichner ER. Blood doping: Infusions, erythropoietin and artificial blood. Sports Med 2007;37:389-91.
10. Lundby C, Robach P, Saltin B. The evolving science of detection of 'blood doping'. Br J Pharmacol 2012;165:1306-15.
11. Birkeland KI, Stray-Gundersen J, Hemmersbach P, et al. Effect of rhEPO administration on serum levels of sTfR and cycling performance. Med Sci Sports Exerc 2000;32:1238-43.
12. Reichel C. Recent developments in doping testing for erythropoietin. Anal Bioanal Chem 2011;401:463-81.
13. Shermer M. The doping dilemma. Sci Am 2008;298:82-9.
14. Sottas PE, Robinson N, Saugy M. The athlete's biological passport and indirect markers of blood doping. Handb Exp Pharmacol 2010;195:305-26.
15. Lasne F, de Ceaurriz J. Recombinant erythropoietin in urine. Nature 2000;405:635.
16. Ashenden M, Varlet-Marie E, Lasne F, et al. The effects of microdose recombinant human erythropoietin regimens in athletes. Haematologica 2006;91:1143-4.
17. Lundby C, Achman-Andersen NJ, Thomsen JJ, et al. Testing for recombinant human erythropoietin in urine: problems associated with current anti-doping testing. J Appl Physiol 2008;105:417-19.
18. Parisotto R, Gore CJ, Emslie KR, et al. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. Haematologica 2000;85:564-72.
19. Gore CJ, Parisotto R, Ashenden MJ, et al. Second-generation blood tests to detect erythropoietin abuse by athletes. Haematologica 2003;88:333-44.
20. Ashenden M, Gough CE, Garnham A, et al. Current markers of the Athlete Blood Passport do not flag microdose EPO doping. Eur J Appl Physiol 2011;9:2307-14.
21. Borno A, Aachmann-Andersen NJ, Munch-Andersen T, et al. Screening for recombinant human erythropoietin using [Hb], reticulocytes, the OFF(hr score), OFF (z score) and Hb(z score): status of the blood passport. Eur J Appl Physiol 2010;109:537-43.
22. Schumacher YO, Grathwohl D, Barturen JM, et al. Haemoglobin, haematocrit and red blood cell indices in elite cyclists. Are the control values for blood testing valid? Int J Sports Med 2000;21:380-5.
23. Ashenden MJ, Hahn AG, Martin DT, et al. A comparison of the physiological response to simulated altitude exposure and r-HuEpo administration. J Sports Sci 2001;19:831-7.
24. Ashenden MJ, Gore CJ, Parisotto R, et al. Effect of altitude on second-generation blood tests to detect erythropoietin abuse by athletes. Haematologica 2003;88:1053-62.
25. Ashenden M. Contemporary issues in the fight against blood doping in sport. Haematologica 2004;89:901-3.
26. Schumacher YO, Saugy M, Pottgiesser T, et al. Detection of EPO doping and blood doping: The haematological module of the athlete biological passport. Drug Test Anal 2012;4:846-53.
27. Sottas PE, Robinson N, Fischetto G, et al. Prevalence of blood doping in samples collected from elite track and field athletes. Clin Chem 2011;57:762-9.
28. Zorzoli M, Rossi F. Implementation of the biological passport: The experience of the International Cycling Union. Drug Test Anal 2010;2:542-7.
29. Pottgiesser T, Sottas P-E, Echteler T, et al. Detection of autologous blood doping with adaptively evaluated biomarkers of doping: A longitudinal blinded study. Transfusion 2011;51:1707-15.
30. Lippi G, Plebani M. Athlete's biological passport: To test or not to test? Clin Chem Lab Med 2011;49:1393-5.
31. Morkeberg J, Sharpe K, Karstoft K, et al. Detection of microdoses of rhEPO with the MAIIA test. Scand J Med Sci Sports 2013.doi: 10.1111/sms.12049.
32. Sanchis-Gomar F, Martinez-Bello VE, Gomez-Cabrera MC, et al. Current limitations of the Athlete's Biological Passport use in sports. Clin Chem Lab Med 2011;49:1413-15.
33. Snyder M, Gerstein M. Genomics. Defining genes in the genomics era. Science 2003;300:258-60.
34. Reichel C. OMICS-strategies and methods in the fight against doping. Forensic Sci Int 2011;213:20-34.
35. Bilitewski U. DNA microarrays: An introduction to the technology. Methods Mol Biol 2009;509:1-14.
36. Varlet-Marie E, Audran M, Ashenden M, et al. Modification of gene expression: help to detect doping with erythropoiesis-stimulating agents. Am J Hematol 2009;84:755-9.
37. Pottgiesser T, Schumacher YO, Funke H, et al. Gene expression in the detection of autologous blood transfusion in sports-a pilot study. Vox Sang 2009;96:333-6.
38. Durussel J, Daskalaki E, Anderson M, et al. Haemoglobin mass and running time trial performance after recombinant human erythropoietin administration in trained men. PLoS ONE 2013;8:e56151.
39. Wondimu DH, Durussel J, Mekonnen W, et al. Blood parameters and running performance of Kenyan and Caucasian endurance trained males after rHuEpo administration. Medi Sci Sports Exerc 2013;45:402-5.
40. Durussel J, McClure JD, McBride MW, et al. Blood gene expression profiles of Kenyan and Caucasian endurance trained males after rHuEpo administration. 60th American College of Sports Medicine Annual Meeting and 4th World Congress on Exercise is Medicine of the American College of Sports Medicine. Medicine and Science in Sports and Exercise. Indianapolis, USA, 2013.
41. Durussel J, McClure JD, McBride MW, et al. Validation of blood gene expression profiles post rHuEpo administration. 61th American College of Sports Medicine Annual Meeting and 5th World Congress on the Role of Inflammation in Exercise, Health and Disease. Medicine and Science in Sports and Exercise. Orlando, USA, 2014.
42. Millet GP, Roels B, Schmitt L, et al. Combining hypoxic methods for peak performance. Sports Med 2010;40:1-25.
43. Bonetti DL, Hopkins WG. Sea-level exercise performance following adaptation to hypoxia: A meta-analysis. Sports Med 2009;39:107-27.
44. Levine BD, Stray-Gundersen J. 'Living high-training low': effect of moderate-altitude acclimatization with low-altitude training on performance. J Appl Physiol 1997;83:102-12.
45. Rupert JL. Transcriptional profiling: A potential anti-doping strategy. Scand J Med Sci Sports 2009;19:753-63.
46. Buttner P, Mosig S, Lechtermann A, et al. Exercise affects the gene expression profiles of human white blood cells. J Appl Physiol 2007;102:26-36.
47. Connolly PH, Caiozzo VJ, Zaldivar F, et al. Effects of exercise on gene expression in human peripheral blood mononuclear cells. J Appl Physiol 2004;97:1461-9.
48. Girard O, Mendez-Villanueva A, Bishop D. Repeated-sprint ability-part I: factors contributing to fatigue. Sports Med 2011;41:673-94.
49. The Telegraph (2013) World Anti-Doping Agency calls on the football authorities to do more to combat doping. drugsinsport/9865412/World-Anti-Doping- Agency-calls-on-the-football-authoritiesto- do-more-to-combat-doping.html (accessed on 26 Apr 2013).
50. http://www.deredactie.be/cm/vrtnieuws.english/sports/130913-doping- football-poll (accessed 5 Nov 2013).
51. Sottas P-E, Robinson N, Saugy M, et al. A forensic approach to the interpretation of blood doping markers. Law Prob Risk 2008;7:191-210.
52. Weight LM, Darge BL, Jacobs P. Athletes' pseudoanaemia. Eur J Appl Physiol 1991;62:358-62.
53. Lombardi G, Lanteri P, Fiorella PL, et al. Comparison of the hematological profile of elite road cyclists during the 2010 and 2012 GiroBio ten-day stage races and relationships with final ranking. PLoS ONE 2013;8:e63092.
54. Telford RD, Sly GJ, Hahn AG, et al. Footstrike is the major cause of hemolysis during running. J Appl Physiol 2003;94:38-42.
55. Yusof A, Leithauser RM, Roth HJ, et al. Exercise-induced hemolysis is caused by protein modification and most evident during the early phase of an ultraendurance race. J Appl Physiol 2007;102:582-6.
56. Sharpe K, Hopkins W, Emslie KR, et al. Development of reference ranges in elite athletes for markers of altered erythropoiesis. Haematologica 2002;87:1248-57.
57. Schumacher YO, Ahlgrim C, Ruthardt S, et al. Hemoglobin mass in an elite endurance athlete before, during, and after injury-related immobility. Clin J Sport Med 2008;18:172-3. Pitsiladis